Taurodeoxychloic-Acid-sodium-hydrate-Sodium-taurodeoxycholate-monohydrate-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemETaurodeoxychloic Acid sodium hydrateCat. No.: HY-B1899ACAS No.: 110026-03-4Synonyms: Sodium taurodeoxycholate monohydrate分式: CHNNaOS+分量: 540.71作靶点: Apoptosis; Caspase作通路: Apoptosis储存式: Powder -20C 3 years4C 2 yearsIn solvent -80

2、C 6 months-20C 1 month溶解性数据体外实验 DMSO : 125 mg/mL (231.18 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 1.8494 mL 9.2471 mL 18.4942 mL5 mM 0.3699 mL 1.8494 mL 3.6988 mL10 mM 0.1849 mL 0.9247 mL 1.8494 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。体内实验请根据您的实验动物和给药式选择适当的溶解案，配制前

3、请先配制澄清的储备液，再依次添加助溶剂(为保证实验结果的可靠性，体内实验的作液，建议您现现配，当天使；澄清的储备液可以根据储存条件，适当保存；以下溶剂前的百分 指该溶剂在您配制终溶液中的体积占)：1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.08 mg/mL (3.85 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.08 mg/mL (3.85 mM); Clear solution3

4、. 请依序添加每种溶剂： 10% DMSO 90% corn oil1/2 Master of Small Molecules 您边的抑制剂师www.MedChemESolubility: 2.08 mg/mL (3.85 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Taurodeoxychloic Acid (sodium hydrate) 通过阻断钙介导的凋亡通路和 Caspase-12的活化来阻细胞凋亡。Taurodeoxychloic Acid (sodium hydrate) 被于多种研究，如原发性胆汁性肝硬化 (PBC)，胰岛素抵抗，淀粉样变

5、性，囊性纤维化，胆汁淤积和肌萎缩侧索硬化症。IC50 & Target Caspase-12体内研究 Taurodeoxychloic Acid (TUDCA) is neuroprotective in a transgenic animal model of Huntingtons disease 2.REFERENCES1. Xie Q, et al. Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. Hepatology. 2002Sep;

6、36(3):592-601.2. Keene CD, et al. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntingtons disease. ProcNatl Acad Sci U S A. 2002 Aug 6;99(16):10671-6.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820